Ginkgo Bioworks Holdings (DNA) Cost of Revenue (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Cost of Revenue data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Cost of Revenue fell 24.25% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.6 million (up 252.58% YoY) and the FY2025 annual result came in at $28.9 million, up 381.7% from the prior year.
• Cost of Revenue slipped to $3.1 million in Q1 2026, from $18.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $24.7 million in Q3 2022 to a low of -$153.4 million in Q4 2022.
• A 5-year average of -$2.4 million and a median of $4.7 million in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 3273.68% — and 2025, when it jumped 814.31%.
• Tracing DNA's Cost of Revenue over 5 years: stood at -$153.4 million in 2022, then surged by 95.12% to -$7.5 million in 2023, then surged by 127.66% to $2.1 million in 2024, then jumped by 814.31% to $18.9 million in 2025, then slumped by 83.62% to $3.1 million in 2026.
• The last three Cost of Revenue figures came in at $3.1 million (Q1 2026), $18.9 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.